YMAB EQUITY ALERT: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Y-mAbs Therapeutics, Inc. Investors with Losses to Inquire About Securities Class Action Investigation – YMAB

NEW YORK, Nov. 01, 2022 (GLOBE NEWSWIRE) —

WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) resulting from allegations that Y-mAbs may have issued materially misleading business information to the investing public.

SO WHAT: If you purchased Y-mAbs securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

WHAT TO DO NEXT: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=9496 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

WHAT IS THIS ABOUT: On October 31, 2022, Marketwatch published an article entitled “Y-mAbs Therapeutics shares fall 42% following last week’s FDA advisory committee vote” which stated “[s]hares of Y-mAbs Therapeutics Inc. YMAB, [] plunged 42.5% in premarket trading on Monday after several banks downgraded the company’s stock and a Food and Drug Administration advisory committee voted against approval of the company’s experimental treatment for neuroblastoma patients.”

The article further stated that the “committee on Friday voted 16-0 that there wasn’t enough evidence to say that omburtamab improves overall survival. J.P. Morgan downgraded the stock to underweight from neutral, with analysts saying: ‘We do not think recent newsflow bodes well for investor confidence or for ascribing further pipeline value to follow-on indications which are mostly in their early innings of development.’”

On this news, Y-mAbs’ stock fell sharply during pre-market and intraday trading on October 31, 2022.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

        Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827

GlobeNewswire Distribution ID 8686993